NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,417−0.18%BTC$81,133−0.12%VIX14.81−4.08%live tape · as of 23:00 UTC · 20 Sep
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic
Teva- Pharmaceutical Industries Ltd ADR
TEVA · the NYSE · USD · Market cap $43.2B · 31,173 employees
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
FAIL · Does not pass the screen
37.09 USD
At the last full screen 2026-09-11
Screened 2026-09-11 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 37.09 against the desk's fair-value range, base estimate 50.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price37.09 USD
Fair value50.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-14Read Markdown37.09+0.0% to today
2026-08-14Read Markup34.81+6.5% to today ✓
2026-07-02Read Markdown34.63+7.1% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Teva- Pharmaceutical Industries Ltd ADR holds its Accumulation at $37.09. The statistical read favours the sellers, held for 25 days.
As held on the ledger · 2026-09-11
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 25 days
Price at the screen
$37.09
Valuation
61.82 trailing · 12.08 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.87
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
41.95%
Below 33%
Interest-bearing debt is 42.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
17.83%
Below 49%
Money owed to the company is 17.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Conscience Overlay
Conscience flag · BDS Movement
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Cited by BDS movement as the largest Israeli-headquartered pharmaceutical company, a major component of the Israeli economy. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 34.8% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +13% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Generics Maker Stuck in Low Gear
Picture a pharmacy shelf where every pill costs less than the branded version yet still earns steady money for the company that makes it. Teva sits at that table, turning out generics across dozens of markets with a 9% profit margin and 22% return on equity. The shares trade at 10.4 times forward earnings, well below our $50 fair value, and the business clears our ethical screen.
We still pass. Revenue growth has settled at just 2%, the moat is rated narrow, and the opportunity rating comes back as None. Analyst targets sit at $40, already reflecting some recovery, but the low single-digit top line leaves little room for sustained outperformance.
The real risk is relentless price pressure on generics plus regulatory and legal overhangs that can swing results quickly. A narrow moat means competitors can copy the same moves. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Israel and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TEVA trades on the NYSE (the company is based in Israel). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-14Markdown · changed$37.09+6.5%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 6.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 91%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (10 analysts) rates it strong buy, with a mean price target of $41.
2026-08-14Markup · changed$34.81+0.5%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 91%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (10 analysts) rates it strong buy, with a mean price target of $41.
2026-07-18Markdown$34.63+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 91%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (10 analysts) rates it strong buy, with a mean price target of $41.
2026-07-03Markdown$34.63+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$34.63Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
